UX-DA001 / Shanghai Yuesai Biotech - LARVOL DELTA

Unixell Biotech…announced positive 6-month follow-up data from the first patient in its phase 1 clinical trial for UX-DA001, an iPSC-derived autologous cell therapy for PD. (The Manila Times) - "The patient tolerated the procedure well, with no serious adverse events or adverse events related to the transplanted cells. Significant improvement in motor function: The MDS-UPDRS-III score improved by 21 points during the 'OFF-period' and 9 points during the 'ON-period', representing an improvement ratio exceeding 45% in both states."

P1 data • Parkinson's Disease

UniXell Biotechnology announces the first patient dosed with UX-DA001, an investigational autologous iPSC based cell therapy for the treatment of Parkinson's disease, in its Phase 1 study (The Manila Times) - "Shanghai UniXell Biotechnology Co., Ltd...announced the successful first administration of its proprietary Parkinson's disease cell drug UX-DA001 in China in March 2025. The Phase I clinical trial aims to evaluate the safety, tolerability, and preliminary efficacy of UX-DA001 in patients with Parkinson's disease."

Trial status • Parkinson's Disease